Predictions
Arbutus Biopharma Corp.
Start price
Target price
Perf. (%)
€2.39
08.07.21
08.07.21
-
08.07.22
08.07.22
13.98%
08.07.22
08.07.22
Arbutus Biopharma Corp.
Start price
Target price
Perf. (%)
€3.23
28.06.21
28.06.21
-
28.06.22
28.06.22
-24.89%
29.06.22
29.06.22
Nymox Pharmaceutical Corp.
Start price
Target price
Perf. (%)
€1.38
28.06.21
28.06.21
€2.50
28.06.22
28.06.22
-71.16%
29.06.22
29.06.22
Aurinia Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€9.94
06.03.22
06.03.22
-
06.03.23
06.03.23
-0.02%
30.04.22
30.04.22
Risky Investment
Arbutus Biopharma Corp.
Start price
Target price
Perf. (%)
€3.03
11.11.21
11.11.21
€2.90
11.11.22
11.11.22
-21.78%
28.04.22
28.04.22
Differentiated customer and product portfolio
Lower EBIT Margin than peer group
High valuation
Very low/no dividend yield expected
Aurinia Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€9.71
15.07.21
15.07.21
-
15.07.22
15.07.22
1.92%
23.04.22
23.04.22
Nymox Pharmaceutical Corp.
Start price
Target price
Perf. (%)
€1.15
21.03.22
21.03.22
€4.00
21.03.23
21.03.23
11.30%
04.04.22
04.04.22
Nymox Pharmaceutical Corp.
Start price
Target price
Perf. (%)
€1.15
19.03.22
19.03.22
€0.000
19.03.23
19.03.23
11.30%
02.04.22
02.04.22
Aurinia Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€15.27
20.02.22
20.02.22
-
20.02.23
20.02.23
-34.89%
05.03.22
05.03.22
Aurinia Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€17.02
16.02.22
16.02.22
-
16.02.23
16.02.23
-10.26%
19.02.22
19.02.22
Could be worthwhile Investment >10% per year
Aurinia Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€14.52
23.01.22
23.01.22
-
23.01.23
23.01.23
7.06%
06.02.22
06.02.22
Could be worthwhile Investment >10% per year
Arbutus Biopharma Corp.
Start price
Target price
Perf. (%)
€2.30
23.01.22
23.01.22
-
23.01.23
23.01.23
15.82%
06.02.22
06.02.22
Risky Investment
Aurinia Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€16.62
14.01.22
14.01.22
-
14.01.23
14.01.23
-12.67%
22.01.22
22.01.22
Could be worthwhile Investment >10% per year
Xenon Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€14.20
18.09.21
18.09.21
€40.00
31.12.23
31.12.23
61.97%
16.12.21
16.12.21
Could be very worthwhile Investment >20% year
Aptose Biosciences
Start price
Target price
Perf. (%)
€3.22
11.06.21
11.06.21
€4.00
11.06.22
11.06.22
-69.57%
14.12.21
14.12.21
Could be worthwhile Investment >10% per year
Arbutus Biopharma Corp.
Start price
Target price
Perf. (%)
€3.91
01.12.21
01.12.21
-
01.12.22
01.12.22
-1.46%
11.12.21
11.12.21
Aurinia Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€17.00
28.11.21
28.11.21
-
28.11.22
28.11.22
7.65%
11.12.21
11.12.21
Could be worthwhile Investment >10% per year
Arbutus Biopharma Corp.
Start price
Target price
Perf. (%)
€3.96
01.12.21
01.12.21
€6.00
01.12.22
01.12.22
-2.70%
11.12.21
11.12.21
Could be worthwhile Investment >10% per year
Innovative
Good culture
Below average Management
Xenon Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€26.00
05.10.21
05.10.21
-
05.10.22
05.10.22
-10.00%
08.12.21
08.12.21
Probably not worthwhile Investment
Aurinia Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€17.50
22.11.21
22.11.21
-
22.11.22
22.11.22
-2.83%
28.11.21
28.11.21
Risky Investment
Aurinia Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€21.37
22.11.21
22.11.21
-
22.11.22
22.11.22
-20.45%
27.11.21
27.11.21
Aurinia Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€23.97
15.11.21
15.11.21
-
15.11.22
15.11.22
-28.16%
26.11.21
26.11.21
Could be worthwhile Investment >10% per year
Arbutus Biopharma Corp.
Start price
Target price
Perf. (%)
€3.45
16.11.20
16.11.20
-
16.11.21
16.11.21
-14.81%
17.11.21
17.11.21
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
Stable Large shareholder and/or long term investor
Future proof or reliable business model
Aurinia Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€26.17
03.11.21
03.11.21
-
03.11.22
03.11.22
-8.41%
15.11.21
15.11.21
Risky Investment
Arbutus Biopharma Corp.
Start price
Target price
Perf. (%)
€2.45
10.07.21
10.07.21
€1.90
10.07.22
10.07.22
23.96%
11.11.21
11.11.21
Differentiated customer and product portfolio
Lower EBIT Margin than peer group
High valuation
Very low/no dividend yield expected